HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

Hims stock soared 12% today and was trading at $56.00 at press time. Trading volume was way up, and the stock’s been on a tear all week. Investors seem fired up about where the company’s headed in ...

HIMS accelerates global growth with ZAVA buyout, Canadian launch, and soaring EPS estimates pointing to 177.8% upside.

Stock indexes in the U.S. moved upward Wednesday as the gained 1.14%. Meanwhile, the increased 0.78%, and the rose 0.61%.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...